**SUPPLEMENTARY MATERIALS**

**Table 1:** Overall outcomes at five-year-FU

**Figure 1:** ROC curve: Independent predictors for secondary endpoint: Baseline creatinine, baseline MVG and baseline sPAP

**Figure 2:** Cox regression analysis: Combined independent baseline predictors for primary endpoint: Baseline sPAP>45 mmHg, baseline MVG>1,5mmHg and baseline creatinine>2mg/dl)

**Figure 3:** Kaplan-Meier curve: All-cause mortality in groups during the follow-up (sMR: secondary mitral regurgitation, pMR: primary mitral regurgitation)

**Figure 4:** Kaplan-Meier curve: Cumulative incidence of Re-dos in groups including surgical and interventional therapies (sMR: secondary mitral regurgitation, pMR: primary mitral regurgitation)

**Table 1:** Overall outcomes at five-year-FU

|  |  |  |  |
| --- | --- | --- | --- |
|  | sMR | pMR | p-Value |
| MR≤II, % | 91 | *86.4* | 0.9 |
| Functional NYHA class >II, % | 34.6 | *33.3* | 0.6 |
| Mortality, % | 19 | *10* | 0.05 |
| Interventional failure, % | 3.1 | *8.6* | 0.04 |
| Re-Clipping, % | 6.8 | *4.7* | 0.1 |
| Mitral valve surgery, % | 0.6 | *1.9* | 0.08 |
| Other interventions, % | 1.8 | *0.9* | 0.2 |

*MR: Mitral regurgitation; NYHA: New York Heart Association*

**Figure 1:** ROC curve: Independent predictors for secondary endpoint

****

**Figure 2:** Cox regression analysis: Combined independent predictors for primary endpoint

**Figure 3:** Kaplan-Meier curve: All-cause mortality in groups during the follow-up (sMR: secondary mitral regurgitation, pMR: primary mitral regurgitation)



**Figure 4:** Kaplan-Meier curve: Cumulative incidence of Re-dos in groups including surgical and interventional therapies (sMR: secondary mitral regurgitation, pMR: primary mitral regurgitation)

